-
Tytuł:
-
The pleiotropic beneficial intervention of olive oil intake on the Alzheimer's disease onset via fibrinolytic system.
-
Autorzy:
-
Tzekaki EE; Laboratory of Biochemistry, Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Makedonia, Greece.
Tsolaki M; 1(st) Department of Neurology, Medical School, 'AHEPA' General Hospital Medical School, Aristotle University of Thessaloniki, Faculty of Health Sciences, 54124 Thessaloniki, Makedonia, Greece; Greek Association of Alzheimer's Disease and Related Disorders - GAADRD, Greece. Electronic address: .
Pantazaki ΑA; Laboratory of Biochemistry, Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Makedonia, Greece. Electronic address: .
Geromichalos G; Laboratory of Biochemistry, Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Makedonia, Greece.
Lazarou E; Greek Association of Alzheimer's Disease and Related Disorders - GAADRD, Greece.
Kozori M; Greek Association of Alzheimer's Disease and Related Disorders - GAADRD, Greece.
Sinakos Z; Emeritus Professor of Hematology, Medical School, Aristotle University of Thessaloniki, Faculty of Health Sciences, Greece.
-
Źródło:
-
Experimental gerontology [Exp Gerontol] 2021 Jul 15; Vol. 150, pp. 111344. Date of Electronic Publication: 2021 Apr 06.
-
Typ publikacji:
-
Journal Article; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Publication: Tarrytown Ny : Elsevier Science
Original Publication: Oxford.
-
MeSH Terms:
-
Alzheimer Disease*
Cognitive Dysfunction*
Humans ; Olive Oil ; Oxidative Stress ; Tissue Plasminogen Activator
-
Contributed Indexing:
-
Keywords: (PAI-1); (tPA); Extra virgin olive oil (EVOO); MICOIL clinical trial; Mild Cognitive Impairment (MCI); Plasminogen activator inhibitor 1; Tissue plasminogen activator; a2-antiplasmin (α2ΑP)
-
Molecular Sequence:
-
ClinicalTrials.gov NCT03362996
-
Substance Nomenclature:
-
0 (Olive Oil)
EC 3.4.21.68 (Tissue Plasminogen Activator)
-
Entry Date(s):
-
Date Created: 20210409 Date Completed: 20210702 Latest Revision: 20210702
-
Update Code:
-
20240105
-
DOI:
-
10.1016/j.exger.2021.111344
-
PMID:
-
33836262
-
The daily consumption of Extra Virgin Olive Oil (EVOO) in Mediterranean nutrition is tightly associated with lower frequency of many diseases' appearance, including Alzheimer's disease (AD). Fibrinolytic system is already assumed to be involved in AD pathophysiology through various factors, especially plasminogen activator inhibitor-1 (PAI-1), a2-antiplasmin (α2ΑP) and tissue plasminogen activator (tPA). We, here, present a biochemical study, as a continuation of a clinical trial of a cohort of 84 participants, focusing on the pleiotropic effect of the annual EVOO consumption on the fibrinolytic factors of Mild Cognitive Impairment (MCI) patients. The levels of all these fibrinolytic factors, measured by Enzyme-Linked Immunosorbent Assay (ELISA) method, were reduced in the serum of MCI patients annually administered with EVOO, versus not treated MCI patients, as well as AD patients. The well-established AD hallmarks (Aβ1-40 and Aβ1-42 species, tau, and p-tau) of MCI patients' group, annually administered with EVOO, were restored to levels equal to those of the cognitively-healthy group; in contrast to those patients not being administered, and their AD hallmarks levels increased at the end of the year. Moreover, one of the EVOO annual consumption multimodal effects on the MCI patients focused on the levels of an oxidative stress trademark, malondialdehyde (MDA), which displayed also a visible quenching; On the other hand, an increase exhibited in the MCI patients not consuming EVOO one year after, was attributed to the lack of the EVOO anti-oxidative properties. These outcomes are exploitable towards the establishment of natural products like EVOO, as a preventive remedy fighting this neurodegenerative disorder, AD. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/ct2/show/NCT03362996 MICOIL gov Identifier: NCT03362996.
(Copyright © 2021. Published by Elsevier Inc.)
